Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 4, Issue 3, 2010, Pages 283-290

  Lakatos, Peter Laszlo ^a   Czegledi, Zsofia ^b   David, Gyula ^c   Kispal, Zsofia ^a   Kiss, Lajos S ^a   Palatka, Karoly ^d   Kristof, Tunde ^e   Nagy, Ferenc ^f   Salamon, Agnes ^g   Demeter, Pal ^h   Miheller, Pal ^a   Szamosi, Tamas ^b   Banai, Janos ^b   Papp, Maria ^d   Bene, Laszlo ⁱ   Kovacs, Agota ⁱ   Racz, Istvan ^j   Lakatos, Laszlo ^c  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b State Health Centre   (Hungary)

^c Csolnoky F County Hospital   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e Borsod County Teaching Hospital   (Hungary)

^f UNIVERSITY OF SZEGED   (Hungary)

^g Szekszard County Hospital   (Hungary)

^h ST JOHN'S HOSPITAL   (Hungary)

ⁱ Peterfi Hospital   (Hungary)

^j Petz Aladar Univ Teach Hosp 9024   (Hungary)

more..

Author keywords

Adherence; CD; Complementary medicine; IBD; UC

Indexed keywords

ACUPUNCTURE; ADULT; ALTERNATIVE MEDICINE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; DIET THERAPY; EDUCATIONAL STATUS; ENTERITIS; HERBAL MEDICINE; HOMEOPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERVIEW; MAJOR CLINICAL STUDY; PHENOTYPE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; ULCERATIVE COLITIS;

EID: 77955275765     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.11.011     Document Type: Article

References (28)

1. Lakatos L., Fischer S., Lakatos L., Gal I., Papp J. Current concept on the pathogenesis of IBD: crosstalk between genetic and microbial factors. Pathogenic bacteria, altered bacterial sensing or changes in mucosal integrity take "toll"?. World J Gastroenterol 2006, 12:1829-1840.
2. Lakatos P.L. Recent trends in the epidemiology of inflammatory bowel diseases: up or down?. World J Gastroenterol 2006, 12:6102-6108.
3. Kane S.V., Cohen R.D., Aikens J.E., Hanauer S.B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001, 96:2929-2933.
4. Cervenỳ P., Bortlík M., Kubena A., Vlcek J., Lakatos P.L., Lukás M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007, 13:1244-1249.
5. Horne R., Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999, 47:555-567.
6. Sewitch M.J., Abrahamowicz M., Barkun A., Bitton A., Wild G.E., Cohen A., Dobkin P.L. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003, 98:1535-1544.
7. Rubin G., Hungin A.P., Chinn D., Dwarakanath A.D., Green L., Bates J. Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther 2002, 16:1889-1893.
8. Bernal I., Domenech E., Garcia-Planella E., Marín L., Mañosa M., Navarro M., Cabré E., Gassull M.A. Medication-taking behaviour in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006, 51:2165-2169.
9. Beardon P.H., McGilchrist M.M., McKendrick A.D., McDevitt D.G., MacDonald T.M. Primary non-compliance with prescribed medication in primary care. BMJ 1993, 307:846-848.
10. Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008, 27(Suppl 1):9-14.
11. Ediger J.P., Walker J.R., Graff L., Lix L., Clara I., Rawsthorne P., Rogala L., Miller N., McPhail C., Deering K., Bernstein C.N. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007, 102:1417-1426. 10.1111/j.1572-0241.2007.01212.x, PMID: 17437505.
12. D'Incà R., Bertomoro P., Mazzocco K., Vettorato M.G., Rumiati R., Sturniolo G.C. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2008, 27:166-172.
13. Mantzaris G.J., Roussos A., Kalantzis C., Koilakou S., Raptis N., Kalantzis N. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission?. Inflamm Bowel Dis. 2007, 13:446-450.
14. Shale M.J., Riley S.A. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003, 18:191-198.
15. Langmead L., Rampton D.S. Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2006, 23:341-349.
16. Smart H.L., Mayberry J.F., Atkinson M. Alternative medicine consultations and remedies in patients with the irritable bowel syndrome. Gut 1986, 27:826-828.
17. Rawsthorne P., Shanahan F., Cronin N.C., Anton P.A., Löfberg R., Bohman L., Bernstein C.N. An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease. Am J Gastroenterol 1999, 94:1298-1303.
18. Hilsden R.J., Verhoef M.J., Best A., Pocobelli G. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastreoenterol 2003, 98:1563-1568.
19. Eisenberg D.M., Kessler R.C., Foster C., Norlock F.E., Calkins D.R., Delbanco T.L. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993, 328:246-252.
20. Li F.X., Verhoef M.J., Best A., Otley A., Hilsden R.J. Why patients with inflammatory bowel disease use or do not use complementary and alternative medicine: a Canadian national survey. Can J Gastroenterol 2005, 19:567-573.
21. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989, 24(suppl 170):2-6.
22. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., Caprilli R., Colombel J.F., Gasche C., Geboes K., Jewell D.P., Karban A., Loftus E.V., Peña A.S., Riddell R.H., Sachar D.B., Schreiber S., Steinhart A.H., Targan S.R., Vermeire S., Warren B.F. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl A):5-36.
23. Mantzaris G.J., Roussos A., Kalantzis C., Koilakou S., Raptis N., Kalantzis N. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission?. Inflamm Bowel Dis. 2007, 13:446-450.
24. Greenley R.N., Stephens M., Doughty A., Raibon T., Kungathasan S. Barriers to adherence among adolescents with inflammatory bowel disease. Inflamm Bowel Dis May 11 2009, Electronic publication ahead of print. 10.1002/ibd.20988.
25. Hommel K.A., Davis C.M., Baldassano R.N. Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2009, 15:589-593.
26. Belaiche J., Desager J.P., Horsmans Y., Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol. 2001, 36:71-76.
27. Joos S., Rosemann T., Szecsenyi J., Hahn E.G., Willich S.N., Brinkhaus B. Use of complementary and alternative medicine in Germany - a survey of patients with inflammatory bowel disease. BMC Complement Altern Med. 2006, 6:19.
28. Burgmann T., Rawsthorne P., Bernstein C.N. Predictors of alternative and complementary medicine use in inflammatory bowel disease: do measures of conventional health care utilization relate to use?. Am J Gastroenterol 2004, 99:889-893.